# DAN-311

Source: https://onco.cc/drugs/dan-311/  
OnCo record `dan-311` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DAN-311 is an experimental targeted high-capacity drug conjugate from Dantari, in preclinical development for HER2-positive breast cancer and HER2-low breast cancer; its current status is not stated.

## Summary

DAN-311 is a targeted high-capacity drug conjugate from Dantari. A drug conjugate on the T-HDC platform for HER2-positive and HER2-low breast cancer. Its furthest stage is preclinical development, for HER2-positive breast cancer and HER2-low breast cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Planned to enter the clinic in late 2023 (Dec 2022 coverage); no registry study names DAN-311. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: DAN-311
- Modality: Targeted high-capacity drug conjugate
- Mechanism: A drug conjugate on the T-HDC platform for HER2-positive and HER2-low breast cancer.

## Sources

- Dantari: biospace.com: https://www.biospace.com/dantari-launches-with-47m-to-make-better-adcs

## Connected records

- companies: [Dantari](https://onco.cc/companies/dantari/)

---
JSON: https://onco.cc/api/v1/entities/dan-311.json